 |
 |
Barbara Mallut <[log in to unmask]>wrote: <<<I find it interesting that some drugs which have been around for years as have several of those used to prevent tissue rejection in organ transplant patients, and were found to restore some brain function in patients with certain brain diseases would need FURTHER "human testing" to see if they'd work in restoring brain function in PD sufferers, Alzheirmers patients, and certain other brain disorders. Since the drugs ARE already approved by the FDA, and ARE already in use nation-wide (and world-wide, presumably), IF they DO work in restoring some brain function to those with certain disorders of the brain, why not just go whole-hog and do a mass testing with several thousand persons having the particlar brain disorders the drugs seem to work for?>>> And, Kenneth Rowland <[log in to unmask]> wrote: <<BALTIMORE - Scientists are encouraged by early studies that show drugs used in organ transplants can regenerate cells damaged by Alzheimer's, Parkinson's and related diseases of the nervous system. Test-tube experiments, as well as trials using rats and monkeys, are showing that modified versions of drugs such as FK506 and cyclosporin can help restore damaged nerve cells in the brain and nervous system, neuroscientist Solomon Snyder said Monday. "It's clearly something worth studying," said Snyder, a professor of neuroscience, pharmacology and psychiatry at Johns Hopkins University School of Medicine. Bruce Gold, a pioneer in the field and professor at Oregon Health Sciences University in Portland, cautioned that it will be a while before the drugs are used in humans. ------------------------------------------------------------------------ Pardon my ignorance, but if these drugs are being used for organ transplant recipients aren't these humans? Its seems highly likely that some of the many organ recipients would be PWP and the drugs effects on PD could be evaluated. Ken Rowland :-)>> These comments are "on the mark". There may be other requirements such as there must have been some specific neural damage or different amount or delivery of the drug to the brain, et cetera; but, there is certainly enough potential benefit that researchers should attempt to gain access to recipient of the drugs to ascertain if any might be potentially benefitted. -- ron 1936, dz PD 1984 Ridgecrest, California Ronald F. Vetter <[log in to unmask]> http://www.ridgecrest.ca.us/~rfvetter